Use the hyperlinks, where available to access additional clinical trial information.
A Phase II Prospective Trial of Stereotactic Hypofractionated Radiation for Multiple (3-10) cerebral metastases including Neurological and Cognitive assessment
Other Non-Commercial Sponsor
Intergrated Clinical Oncology Network Pty Ltd (ICON)
The purpose of this study is to investigate whether improved radiation planning technology that conforms to the shape and size of the cancer, can be used to treat multiple sites of cancer within the brain, and at the same time protect and preserve your brain (memory and cognitive) function.
Who is it for? You may be eligible to join this study if you are aged 18 years or above and have been diagnosed with 3-10 measurable cerebral metastases, i.e. your cancer has spread to three or more spots on the brain.
Study details: All participants in this study will receive a new treatment called Hypofractionated Stereotactic Radiotherapy. This is highly focused radiation given in one or a few (5-6) treatments. Robotic targeting is used to avoid important parts of the normal brain. Where previous treatment for multiple sites of cancer within the brain has involved giving radiation to the whole brain, this treatment will allow us to treat multiple areas at the same time. The aim is to avoid the use of whole brain radiation that can affect the memory structures within the brain such as the hippocampus, thus preserving brain (memory and cognitive) function. The trial will use software called "BrainLab Elements (Trademark)". This software will help the radiation oncologist to plan and deliver the radiotherapy treatment. All participants will be monitored throughout treatment for safety. They will also be asked to undergo MRI scans and complete some questionnaires at the start of the study and at 3 and 6 months after treatment to assess neurocognitive functioning, disease response, and quality of life. We estimate that this study will contribute further to the research into using radiotherapy to control cancers that have spread to the brain, while minimising the effects on brain function.